Armata Pharmaceuticals – Page 6 – BioScience Managers

AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

19th March 2018/in Armata Pharmaceuticals, Portfolio Companies

CATEGORY: Featured Monday, March 19, 2018 4:10 pm EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The promising clinical results I have observed to-date support the potential of bacteriophage therapeutics to be a safe and potent adjunct treatment for serious bacterial infections.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company […]

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights

14th March 2018/in Armata Pharmaceuticals, Portfolio Companies

Announced positive topline results for the first seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program. Treatment was well tolerated with 86% of patients achieving treatment success Signed a Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs Completed a public offering of common stock in Jan. 2018 for […]

AmpliPhi to Collaborate with the U.S. Department of Veterans Affairs on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

13th March 2018/in Armata Pharmaceuticals, Portfolio Companies

CATEGORY: Featured Tuesday, March 13, 2018 6:50 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “We are delighted to collaborate with the U.S. Department of Veterans Affairs on the compassionate use of AB-SA01 and AB-PA01 within the VA Palo Alto Health Care System” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage […]

AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock

10th January 2018/in Armata Pharmaceuticals, Portfolio Companies

CATEGORY: Featured Wednesday, January 10, 2018 6:00 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a public offering of 4,000,000 shares of its common stock, offered at […]

AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock

9th January 2018/in Armata Pharmaceuticals, Portfolio Companies

CATEGORY: Featured Tuesday, January 9, 2018 5:13 pm EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it intends to offer shares of its common stock in a public offering. H.C. […]

AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01

3rd January 2018/in Armata Pharmaceuticals

Seven patients with serious, life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01, with six patients, 86%, achieving treatment success Treatment was well tolerated in all patients, with over 500 doses administered intravenously or by inhalation AmpliPhi expects to continue its expanded access clinical strategy in 2018, review data with the FDA […]

AmpliPhi Biosciences Provides Corporate and Strategic Update

14th December 2017/in Armata Pharmaceuticals

Under single-patient expanded access program, seven patients with serious and life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01 in 2017. Company plans to present topline results in early 2018 Company expects to continue its expanded access clinical strategy in 2018, review data with FDA in mid-2018 and initiate Phase 2 or […]

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights

14th November 2017/in Armata Pharmaceuticals

Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational First-in-human intravenous dosing of AB-SA01 as part of expanded access treatment of a patient […]

AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

11th September 2017/in Armata Pharmaceuticals, Portfolio Companies

A patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines CATEGORY: Featured Monday, September 11, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We continue implementation of our strategy to work with leading infectious disease physicians in the United States and Australia and […]

AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

6th September 2017/in Armata Pharmaceuticals, Portfolio Companies

Wednesday, September 6, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “The R&D tax rebate is an important source of non-dilutive capital and we appreciate the Australian government’s support as we develop our novel bacteriophage therapies aimed at combatting the growing global threat of antibiotic resistance” SAN DIEGO–(BUSINESS […]